SCHEMBL10036044

SCHEMBL10036044

CCN1/C(=C/c2sc3c4ccccc4ccc3[n+]2CC)Sc2c1ccc1ccccc21

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 6/20 0.76
PRMT5 O14744 1/20 0.50
CARM1 Q86X55 1/20 0.50
PRMT8 Q9NR22 1/20 0.50
MEN1 O00255 9/20 0.43
KMT2A Q03164 9/20 0.43
HTT P42858 8/20 0.43
NPC1 O15118 8/20 0.43
RAB9A P51151 8/20 0.43
POLB P06746 6/20 0.43
MAPT P10636 6/20 0.43
LMNA P02545 5/20 0.43
NPSR1 Q6W5P4 5/20 0.43
HSP90AA1 P07900 4/20 0.43
MAPK1 P28482 4/20 0.43
PKM P14618 4/20 0.43
NR2F2 P24468 3/20 0.43
KDM4E B2RXH2 3/20 0.43
ALPG P10696 2/20 0.43
ALPL P05186 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10449113 0.89 PRMT1 (0.62) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL10819530 0.88 PRMT1 (0.66) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL10035991 0.88 PRMT1 (0.73) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL13222318 0.88 PRMT1 (0.73) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL16867335 0.88 PRMT1 (0.73) PRMT1PRMT5CARM1PRMT8MEN1
Iodide SCHEMBL7908601 0.87 PRMT1 (0.73) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL10036054 0.86 PRMT1 (0.83) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL12311445 0.86 PRMT1 (0.83) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL14509025 0.86 PRMT1 (0.69) PRMT1PRMT5CARM1PRMT8MEN1
SCHEMBL10035967 0.86 PRMT1 (1.00) PRMT1PRMT5CARM1PRMT8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT SNCA, PSEN1, CDR2 PRMT1 130/4885PRMT5 584/4885CARM1 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.